Gothenburg, 2013-07-22 12:38 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ), which develops therapeutic cancer vaccines, has received clearance by the Swedish Medical Products Agency to start its second clinical study. The study will be conducted in 12 liver cancer patients at Sahlgrenska University Hospital in Gothenburg. The Company is also about to complete an ongoing clinical trial in kidney cancer patients, thus far showing promising results.
- We are pleased to now be able to offer a new group of cancer patients with no other treatment alternatives access to our cancer vaccine, says Jamal El-Mosleh, CEO of Immunicum.
Immunicum’s patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body's own immune system to attack tumor cells. In 2011, the Nobel Prize in medicine was awarded the discoverer of dendritic cells and their central role in immunological reactions, the same type of cells that Immunicum bases its vaccines on.
- Our vaccine is different from other cancer vaccines of this type that would otherwise have to be produced specifically for each patient, which is expensive, complex and takes time. Moreover, it is physically stressful for the patient who is seriously ill. Our vaccine, INTUVAX®, however, is a standardized vaccine, yet still offering a personalized treatment, says Jamal El-Mosleh.
The liver cancer study will be completed in approximately 2 years and evaluates both the tolerability and efficacy of the treatment. Parallel to this, the Company will complete its ongoing phase I/II-study in renal cancer and intensify the planning of an upcoming phase II-trial.
Immunicum’s patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body's own immune system to attack harmful substances like tumor cells. Immunicum’s shares have been traded since April 22, 2013 on NASDAQ OMX First North under the ticker IMMU.
G&W Fondkommission is chosen as the Company’s Certified Adviser.
Tel: +468-503 000 50. www.gwkapital.se.
For further information please contact:
Jamal El-Mosleh, CEO of Immunicum, 0703-31 90 51,
jamal.el-mosleh@immunicum.com
About Immunicum AB (publ):
Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Because the raw material consists of dendritic cells from healthy donors, Immunicum’s products can be produced in large scale. The vaccines have earlier proven efficacy in animal studies and are now undergoing clinical trials in patients.